ライフサイエンスコーパス: glycoprotein

1 ly an efficiently transported substrate of P-glycoprotein.

2 s the neurotropic nature conveyed by the VSV glycoprotein.

3 in an internal fusion loop of an ebolavirus glycoprotein.

4 ing the complete glycosylated structure of a glycoprotein.

5 d in ISAV HE are not seen in any other viral glycoprotein.

6 y be influenced by the multi-drug exporter P-glycoprotein.

7 G viruses expressing either the Nipah F or G glycoprotein.

8 atitis virus expressing the Zaire ebolavirus glycoprotein.

9 in the gp120 C1 region of the HIV-1 envelope glycoprotein.

10 y through interactions with a viral envelope glycoprotein.

11 to regenerate the Glc1Man9GlcNAc2 moiety on glycoproteins.

12 A but had lower levels of sialylation across glycoproteins.

13 t in culture conditions and among ebolavirus glycoproteins.

14 tions of identifications and quantitation of glycoproteins.

15 red after the ER stress pathway senses viral glycoproteins.

16 -linked glycosylation during the assembly of glycoproteins.

17 tasaccharide motif (Man3GlcNAc2) of N-linked glycoproteins.

18 ctivation of sensitive but not resistant Env glycoproteins.

19 key to understand structure and function of glycoproteins.

20 to O-GlcNAcylated proteins over cell-surface glycoproteins.

21 ered a limiting factor in the sialylation of glycoproteins.

22 glycoproteins, and three gp41 transmembrane glycoproteins.

23 ase for direct core fucosylation of intact N-glycoproteins.

24 in the pituitary, where it suppresses golgi glycoprotein 1 (GLG1) expression and downstream bone mor

25 nd Junin virus (JUNV), bound to the envelope glycoprotein 1 (GP1) with JUNV monoclonal antibodies tar

26 reading frames conventionally called plasmid glycoproteins 1-8 or pGP1-8.

27 HIV vaccine trial included a recombinant HIV glycoprotein 120 (gp120) construct fused to a small port

28 Here, we hypothesized that Glycoprotein 120 (gp120), methamphetamine (METH) and nic

29 at transgenic mice expressing HIV-1 envelope glycoprotein 120 in their central nervous system (HIVgp1

30 ignals are transmitted via the transmembrane glycoprotein 130 by two distinct mechanisms: classic sig

31 IL-6 classic and trans-signaling, or soluble glycoprotein 130 fusion protein, which selectively block

32 rrier (BBB) because of efflux transport by P-glycoprotein (ABCB1) and breast cancer resistance protei

33 Hemagglutinin (HA), a glycoprotein abundant on the virion surface, is importan

34 are required for C1P-mediated increases in P-glycoprotein activity independent of transporter protein

35 Structural comparison of MRP1 and P-glycoprotein advances our understanding of the common an

36 (CRP) concentrations >5 mg/L or alpha-1-acid glycoprotein (AGP) concentrations >1 g/L, 2) the applica

37 of C-reactive protein (CRP) and alpha1-acid glycoprotein (AGP) concentrations on estimates of ID acc

38 ch as C-reactive protein (CRP), alpha-1-acid glycoprotein (AGP), ferritin, and retinol.

39 P-glycoprotein, an ATP-driven efflux pump, regulates perme

40 This method has the potential to simplify glycoprotein analysis by integrating glycan sequencing a

41 ltidrug efflux protein MDR1 (also known as P-glycoprotein and ABCB1).

42 eraction between the gp120 exterior envelope glycoprotein and CD4; (ii) premature triggering of confo

43 old remarkably similar to the dengue virus E glycoprotein and related class II viral fusogens.

44 Glycoproteins and glycolipids of some mammalian species

45 imerized form, which interacts with platelet glycoproteins and integrins, is a major factor and repre

46 timized-enhanced aromatic sequons into other glycoproteins and observed an enhancement in N-glycan oc

47 We quantified the synthesis rates of 847 N-glycoproteins and the degradation rates of 704 glycoprot

48 glycans in the context of N-glycopeptides, N-glycoproteins, and intact antibodies.

49 eins (Env), a trimer of three gp120 exterior glycoproteins, and three gp41 transmembrane glycoprotein

50 Using N-glycoprotein as model, the assay employs two nanoprobes,

51 or RNA that express the virus' Envelope (E) glycoprotein as the antigen.

52 a) is a key component of cell wall polymers, glycoproteins, as well as flavonoids, and signaling pept

53 YKL-40 is a mammalian glycoprotein associated with progression, severity, and

54 CMV virion glycoprotein complexes, including glycoprotein B (gB), gH/gL, and the pentamer, were evalu

55 A-DR7 (DRB1*07:01) tetramers loaded with the glycoprotein B DYSNTHSTRYV (DYS) epitope to characterize

56 We found that OvHV-2 glycoproteins B, H, and L are sufficient for, and viral

57 recursor glycoprotein p62 into the E2 and E3 glycoproteins before assembly with the nucleocapsid is t

58 The HIV-1 envelope (Env) glycoprotein binds to host cell receptors to mediate mem

59 teolytic digestion of the well-characterized glycoproteins bovine ribonuclease B, human transferrin,

60 Expression of the viral glycoprotein, but not a fusion defective mutant, is suff

61 Both Sil1 and Lhs1 are glycoproteins, but how N-glycosylation regulates their f

62 Galectin-3 (Gal-3) can cross-link surface glycoproteins by binding galactose residues that are nor

63 rotein K (gK) and their interactions but not glycoprotein C (gC).

64 hat integrates a periplasmic arabinogalactan glycoprotein-calcium (AGP-Ca(2+) ) capacitor with tip-lo

65 n processes, we extracted four cell membrane glycoproteins, CD146/melanoma cell adhesion molecule (MC

66 and sodium channels Kv1.4 and Nav1.6 and the glycoprotein CD4.

67 The acidic glycoprotein chromogranin A (CHGA) is co-stored/co-secre

68 t is known that the GP1 subunit of the Lassa glycoprotein complex plays a critical role in receptor r

69 Sspn encodes a protein in the dystrophin-glycoprotein complex.

70 tural integrity of the dystrophin associated glycoprotein complex.

71 along with DMD, forms part of the dystrophin-glycoprotein complex.

72 lpha-DG), an integral part of the dystrophin-glycoprotein complex.

73 antibodies targeting epitopes in CMV virion glycoprotein complexes, including glycoprotein B (gB), g

74 rotein concentration >5 mg/L or alpha-1-acid glycoprotein concentration >1 g/L), 2) the application o

75 PNS myelin glycoproteins contain highly abundant sulfated N-glycans

76 tor for the heterologous expression of EHV-1 glycoprotein D (gD) and that the intramuscular immunizat

77 owing: (i) that Cbl, Nectin-1, and the viral glycoprotein D (gD) form a complex in infected cells; (i

78 Glycoprotein D (gD) of herpes simplex virus type 1 (HSV-

79 ll portion of herpes simplex virus 1 (HSV-1) glycoprotein D (gD) so that the first 40 amino acids of

80 Glycoprotein-deleted rabies virus-mediated monosynaptic

81 e CD4-mimetic compound to the HIV-1 envelope glycoproteins depends upon how many of the three subunit

82 cross-link the monomers within the surface E glycoprotein dimers as well as between neighbouring dime

83 shield surrounding conserved regions of the glycoprotein does not enhance vaccine efficacy.

84 l drug-resistant cell lines with activated P-glycoprotein drug efflux pumps compared to drug-sensitiv

85 affecting the function of the transmembrane glycoprotein dystroglycan cause a form of congenital mus

86 The transmembrane glycoprotein dystroglycan functions as a receptor for mu

87 idate the function and structural biology of glycoprotein E-selectin ligands expressed on human PBMCs

88 we describe the crystal structure of the Gn glycoprotein ectodomain from the Asiatic Hantaan virus (

89 d with drug concentration and exceeded the p-glycoprotein efflux when the latter was saturated.

90 Membrane fusion induced by the envelope glycoprotein enables the intracellular replication of HI

91 with interactions between the viral envelope glycoprotein (Env) and cellular CD4 receptors and corece

92 them to cells expressing the HIV-1 envelope glycoprotein (Env) are a promising new weapon for elimin

93 Designing an effective HIV-1 envelope glycoprotein (Env) immunogen for elicitation of broadly

94 G382R and H442Y) into the SIVmac239 envelope glycoprotein (Env) markedly increased its neutralization

95 The development of soluble envelope glycoprotein (Env) mimetics displaying ordered trimeric

96 viruses for having a low number of envelope glycoprotein (Env) spikes per virion, i.e., approximatel

97 ght to generate a form of SIVmac239 envelope glycoprotein (Env) that utilized rhesus CD4 more efficie

98 Soluble, recombinant native-like envelope glycoprotein (Env) trimers of various human immunodefici

99 The homotrimeric HIV-1 envelope glycoprotein (Env) undergoes receptor-triggered structur

100 Interaction of the viral envelope glycoprotein (Env) with a specific cellular receptor is

101 ns that antigenically mimic the HIV envelope glycoprotein (Env), such as the soluble cleaved trimer B

102 a recombinant version of the viral envelope glycoprotein (Env).

103 plication-competent provirus, HIV-1 envelope glycoproteins (Env) are expressed and accumulate on the

104 HIV-1-infected cells presenting envelope glycoproteins (Env) in the CD4-bound conformation on the

105 into cells is mediated by the viral envelope glycoproteins (Env), a trimer of three gp120 exterior gl

106 HIV-1 and its surface envelope glycoproteins (Env), gp120 and gp41, have evolved immune

107 rget cells is mediated by the viral envelope glycoproteins (Env).

108 The envelope glycoproteins (Envs) from human immunodeficiency virus t

109 The envelope glycoproteins (Envs) of HIV-1 continuously evolve in the

110 The envelope glycoproteins (Envs) on the surfaces of HIV-1 particles

111 presence of cells expressing HIV-1 envelope glycoproteins (Envs), these BiKEs activated specifically

112 simplex virus type 1 (HSV-1) is one of four glycoproteins essential for HSV entry and cell fusion.

113 Both proteins are large transmembrane glycoproteins expressed by the podocyte, and both induce

114 ectin (MGL) is a C-type lectin that binds to glycoproteins expressing terminal N-acetylgalactosamine

115 vaccination regimen with a Zaire ebolavirus glycoprotein expression plasmid followed by infection wi

116 The fusion glycoprotein (F) of RSV in either its postfusion (post-F

117 Consistent with these findings, viral glycoproteins fail to mature in SPCA1-deficient cells pr

118 cocci is their interaction with the adhesive glycoprotein fibronectin, which facilitates bacterial ad

119 e approach nominated an extracellular matrix glycoprotein, fibulin-3 (FBLN3, also known as EFEMP1), a

120 activity can alter affinity of cell-surface glycoproteins for the galectin lattice.

121 luenza virus 5 (PIV5) vectors expressing RSV glycoproteins for their immunogenicity and protective ef

122 n of the non-neutralizing face of E2 in this glycoprotein form.

123 cells are infected via interactions between glycoproteins found on the surface of the virus and SLAM

124 ting the receptor-binding surface of the GP1 glycoprotein from Junin virus (JUNV), a hemorrhagic feve

125 reates a steric hindrance for protecting the glycoproteins from degradation by proteases.

126 ntibodies using a set of recombinant surface glycoproteins from Reston, Tai Forest, Bundibugyo, Zaire

127 search and provide insights into elucidating glycoprotein functions and the molecular mechanism of ma

128 Understanding how the Ebola virus surface glycoprotein functions to facilitate entry in cells is a

129 sion protein (F) or the RSV major attachment glycoprotein (G) between the hemagglutinin-neuraminidase

130 Sequence variation of the glycoprotein (G) gene alone was insufficient to distingu

131 VSVs that include the VSV glycoprotein (G) gene, even in most recombinant attenuat

132 The conserved glycoproteins gB and gH-gL are essential for herpesvirus

133 cess hinders VZV and is regulated by a viral glycoprotein, gB.

134 our vital VZV genes, ORF61 and the genes for glycoproteins gC, gE, and gI, was significantly reduced

135 a virus-like vesicle (VLV) in which the VSV glycoprotein gene is expressed from a replicon encoding

136 lding is surveyed by the 170-kDa UDP-glucose:glycoprotein glucosyltransferase (UGGT).

137 act with calnexin cycle proteins UDP-glucose:glycoprotein glucosyltransferase 1 (UGGT1), which cataly

138 n interaction between TAPBPR and UDP-glucose:glycoprotein glucosyltransferase 1 (UGT1), a folding sen

139 Confocal microscopy imaging revealed that glycoprotein Gn colocalizes and accumulates within the e

140 cribe the crystal structure of HTNV envelope glycoprotein Gn, an integral component of the Gn-Gc glyc

141 xpressing the membrane-anchored form of EBOV glycoprotein GP, as an intranasal (i.n.) EBOV vaccine.

142 ntranasal vaccine vector to express the EBOV glycoprotein GP.

143 IgG titers against glycoprotein (gp) 70V1V2 92TH023 increased 14-fold compa

144 ent studies demonstrate that the Ebola virus glycoprotein (GP) acquired an A82V change during the Wes

145 ng lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP) and examined GP-specific CD4 T cell re

146 mino acid sequence, such as A82V in the EBOV glycoprotein (GP) that occurred early in the 2013-16 epi

147 efore vaccination, Zaire Ebola virus (ZEBOV)-glycoprotein (GP)-specific and ZEBOV antibodies were det

148 ntibody cocktails that target the Ebola coat glycoprotein (GP).

149 Although the Ebola virus envelope glycoprotein (GP1,2) antagonizes the trapping of newly f

150 Ebolaviruses have a surface glycoprotein (GP1,2) that is required for virus attachme

151 pathic pain model of perineural HIV envelope glycoprotein gp120 application onto the rat sciatic nerv

152 h binds to the cell surface via the envelope glycoprotein Gp64.

153 The glycoprotein, GPC, is the sole antigen expressed on the

154 Old World arenavirus glycoproteins (GPs) mainly engage alpha-dystroglycan as

155 megalovirus with restored pentameric complex glycoprotein H (gH)/gL/pUL128-131 for prevention of cong

156 This glycoprotein has been further characterized through an i

157 Furthermore, domains B on the E2 glycoproteins have less freedom of movement in the immat

158 issibility is the interaction of the surface glycoproteins hemagglutinin (HA) and neuraminidase (NA)

159 Erythroferrone (ERFE) is a glycoprotein hormone secreted by erythroblasts in respon

160 onses against the hemagglutinin (HA) surface glycoprotein; however, the diversity of HAs across speci

161 cell wall proteins, the hydroxyproline-rich glycoproteins (HRGPs), have characteristic features of I

162 atients who were positive for IgA anti-beta2-glycoprotein I (aB2GP1) and B2A-CIC (n=125); group 2 pat

163 lipid-binding proteins (aPLs), such as beta2 glycoprotein I (beta2GPI).

164 Antibodies anti-beta-2 glycoprotein-I of IgA isotype (IgA-aB2GP1) have been lin

165 ently identified a polymorphism in the Ebola glycoprotein (I544) that enhanced virus entry, but they

166 icks to express Ixodes scapularis antifreeze glycoprotein (iafgp), which encodes a protein with sever

167 which then becomes damaged by apoptosis and glycoprotein Ib alpha chain (CD42b) shedding.

168 platelet rolling via interaction of platelet glycoprotein Ib-IX-V with endothelial-released von Wille

169 The addition of glycoprotein IIb or IIIa inhibitors to fibrinolytic ther

170 The addition of glycoprotein IIb or IIIa inhibitors to fibrinolytic ther

171 Glycoprotein IIb/IIIa (GPIIb/IIIa) is the key receptor i

172 s in outcomes were because of differences in glycoprotein IIb/IIIa inhibitor (GPI) use, a test of med

173 ischemic and bleeding risks associated with glycoprotein IIb/IIIa inhibitors (GPIs) and a potent P2Y

174 AST when either bivalirudin or heparin plus glycoprotein IIb/IIIa receptor inhibitor (GPI) is used.

175 alizing antibodies (bNAbs) by HIV-1 envelope glycoprotein immunogens would be a major advance toward

176 the seroprevalence of myelin oligodendrocyte glycoprotein immunoglobulin G1 (MOG-IgG) and associated

177 ding the necessary stability to the envelope glycoprotein in order to withstand the interaction with

178 P0 protein, the most abundant glycoprotein in PNS myelin and mutations in which at the

179 The inability to produce recombinant hMPV F glycoprotein in the metastable pre-fusion conformation h

180 port the cryoEM structure of a coronavirus S glycoprotein in the postfusion state, showing large-scal

181 n about the alterations of glycosylation and glycoproteins in ASD.

182 ycoproteins and the degradation rates of 704 glycoproteins in biological triplicate experiments, incl

183 the degradation and synthesis rates of many glycoproteins in human cells.

184 ze with a gene involved in the metabolism of glycoproteins in response to chilling stress and may pro

185 N-methyl-D-aspartate receptors (NMDARs) are glycoproteins in the brain central to learning and memor

186 e spinal cord with rabies viruses that carry glycoproteins in their envelopes and that are routinely

187 We found that wild-type Ebola virus glycoprotein, in the context of this platform, provides

188 oordinated action of multiple virus envelope glycoproteins, including gH, gL, and gB.

189 Our results suggest that viral glycoproteins induce a strong innate antiviral response

190 We found that IAV HA glycoproteins induce ER stress, resulting in HA degradat

191 taglandin E2 receptors 1 and 2), abolished P-glycoprotein induction by C1P.

192 eteplase plus parenteral anticoagulants plus glycoprotein inhibitors).

193 cteplase plus parenteral anticoagulants plus glycoprotein inhibitors; RR 1.88 [1.24-2.86] for retepla

194 The coronavirus spike (S) glycoprotein initiates infection by promoting fusion of

195 RSV fusion (F) glycoprotein is a key target for neutralizing antibodies

196 The RSV F glycoprotein is the major RSV neutralization antigen.

197 Beta-trace protein (BTP), a monomeric glycoprotein, is known to indicate cerebrospinal fluid l

198 netic Fe3O4 nanoparticles, to achieve target glycoprotein isolation from biofluid and subsequent glyc

199 ro and affected the localization of UL20 and glycoprotein K (gK) and their interactions but not glyco

200 Glycoprotein K (gK) is a conserved virion glycoprotein o

201 determinants in the amino terminus of HSV-1 glycoprotein K (gK).

202 ers and altered the localization of UL20 and glycoprotein K; and (iii) UL20 is palmitoylated by GODZ,

203 e anion transporter; RhAG, the Rh-associated glycoprotein; KCNN4, the Gardos channel; and ABCB6, an a

204 ome-induced reorganization of the hantaviral glycoprotein lattice.

205 ng of conformational changes in the envelope glycoproteins, leading to irreversible inactivation; and

206 upporting role for the P-selectin/P-selectin glycoprotein ligand 1 axis, followed by (2) firm platele

207 P-selectin glycoprotein ligand-1 (PSGL-1) has long been studied as

208 an extension of membrane-anchored P-selectin glycoprotein ligand-1 (PSGL-1) inhibited integrin-depend

209 eptor L-selectin forms bonds with P-selectin glycoprotein ligand-1 (PSGL-1) on other leukocytes and w

210 "nucleopod," which is capped with P-selectin glycoprotein ligand-1 (PSGL-1).

211 y of protein scaffolds, including P-selectin glycoprotein ligand-1, CD43, and CD44 (rendering the E-s

212 on by selectively inactivating sensitive Env glycoproteins, likely through altering their conformatio

213 Despite growing interest in glycoproteins, little attention has been directed to gly

214 and the maackia amurensis lectin-II binding glycoproteins (MBGs) in 65 children with ASD and 65 age-

215 knowledge on the overall diversity of viral glycoprotein-mediated entry mechanisms.

216 146a and specific for myelin oligodendrocyte glycoprotein (MOG), an autoantigen in the EAE model.

217 by immunization with myelin oligodendrocyte glycoprotein (MOG)35-55 The mechanism of action of GM-CS

218 veloped a more severe myelin oligodendrocyte glycoprotein (MOG)35-55-induced experimental autoimmune

219 eceptor-binding motif in the MojV attachment glycoprotein (MojV-G) indicates a differing host-cell re

220 mucus, the major constituent of which is the glycoprotein Muc2.

221 eus has been shown to produce three salivary glycoproteins named "evasins," which bind to host chemok

222 Anti-MAG (myelin-associated glycoprotein) neuropathy is a disabling autoimmune perip

223 g and ORF2c proteins were massively secreted glycoproteins not associated with infectious particles.

224 iral proteins and includes the B21/22 family glycoproteins not encoded by vaccinia virus strains used

225 rVSV-based vaccine candidate expressing the glycoprotein of a Zaire strain of Ebola virus (ZEBOV).

226 Glycoprotein K (gK) is a conserved virion glycoprotein of all alphaherpesviruses that is not found

227 The envelope glycoprotein of diverse endogenous and exogenous retrovi

228 The envelope (Env) glycoprotein of HIV is the only intact viral protein exp

229 inding affinities between the gp120 envelope glycoprotein of HIV-1 and three broadly neutralizing ant

230 conserved domain of the retroviral envelope glycoprotein of several exogenous as well as endogenous

231 himeric recombinant MuV bearing the F and HN glycoproteins of BMV (rMuVJL5-F/HNBMV) virus and rMuVJL5

232 cs, we identified 84 candidate mitochondrial glycoproteins, of which 44 are novel.

233 ted rabies viruses that carry one of the CDV glycoproteins on their surface.

234 ns B, H, and L are sufficient for, and viral glycoprotein Ov8 can significantly enhance, cell-cell me

235 sufficient to induce membrane fusion, while glycoprotein Ov8 plays an enhancing role by an unknown m

236 ion and activity of the efflux transporter P-glycoprotein (P-gp) encoded by ABCB1 in human hepatoma c

237 ) is to deliver anticancer drug along with P-glycoprotein (P-gp) inhibitor simultaneously.

238 P-glycoprotein (P-gp) is a multidrug transporter that uses

239 P-glycoprotein (P-gp) is a polyspecific ATP-dependent tran

240 Cleavage of the alphavirus precursor glycoprotein p62 into the E2 and E3 glycoproteins before

241 ized sugars that are poor models for natural glycoprotein receptors and do not provide information on

242 vo tropism to cells expressing multiantennal glycoprotein receptors, particularly on endothelial cell

243 However, Scube2, a glycoprotein regulating astrocyte Shh release was decrea

244 Influenza hemagglutinin is a surface glycoprotein related to virus invasion and host immune s

245 structurally well-defined, core-fucosylated glycoproteins remains a challenging task due to the comp

246 ities of the OSTs in vivo using a transgenic glycoprotein reporter system and performed glycoproteomi

247 analysis, we found that VLVs contained viral glycoproteins required for cellular entry, as well as te

248 vironment where the implant is bathed in the glycoprotein-rich salivary fluids that enhance bacterial

249 -rich glioma-inactivated 1 (LGI1), a soluble glycoprotein secreted by neurons.

250 Glycoprotein-specific antibodies were induced in all 20

251 specific polyclonal antibodies (PAbs) or RSV glycoprotein-specific monoclonal antibodies (MAbs), as d

252 e with mice bearing a myelin oligodendrocyte glycoprotein-specific TCR transgene.

253 otein Gn, an integral component of the Gn-Gc glycoprotein spike complex responsible for host cell ent

254 uation using N-glycans released from several glycoprotein standards and human serum proteins, we demo

255 licate experiments, including many important glycoproteins such as CD molecules.

256 -of-care technology is evaluated using Ebola glycoprotein suspended in diluted PBS buffer, human seru

257 ults illuminate how the extracellular matrix glycoprotein tenascin-C in the tumor microenvironment pr

258 nterfere with the cellular defense protein P-glycoprotein, termed transporter interfering compounds (

259 acquire mutations in the hemagglutinin (HA) glycoprotein that abrogate binding of human antibodies.

260 c membrane antigen (PSMA) is a transmembrane glycoprotein that is highly expressed on prostate adenoc

261 Endothelial cells (ECs) express O-glycoproteins that are believed to play important roles

262 eous, core-fucosylated N-glycopeptides and N-glycoproteins that are hitherto difficult to obtain for

263 The identification of OvHV-2 glycoproteins that mediate membrane fusion may help iden

264 sferrin, bovine fetuin and human alpha1-acid glycoprotein, the corresponding deglycosylated peptides,

265 ed the secretion of the powerful angiostatic glycoprotein Thrombospondin 1 independently of Beclin 1

266 The binding of the HIV-1 gp120 glycoprotein to CD4 triggers conformational changes in g

267 e have employed purified and reconstituted P-glycoprotein to study its interaction with ivacaftor as

268 The engagement of the HIV-1 gp120 glycoprotein to the host CD4 protein triggers conformati

269 owever, the relative ability of SIV envelope glycoproteins to bind or utilize these CD4 orthologs has

270 ound and upon the propensity of the envelope glycoproteins to undergo conformational changes.

271 vide a novel model for the interplay between glycoprotein trafficking and paramyxovirus assembly.

272 C1P treatment induced P-glycoprotein transport activity in brain capillaries rap

273 C1P induced P-glycoprotein transport activity without changing transpo

274 by sphingosine 1-phosphate decreases basal P-glycoprotein transport activity.

275 signaling cascade to dynamically regulate P-glycoprotein transport at the BBB and offers potential c

276 Glycoproteins traversing the eukaryotic secretory pathwa

277 es in the conformation of the HIV-1 envelope glycoprotein trimer important for virus entry.

278 arious designs of recombinant HIV-1 envelope glycoprotein trimers that mimic the structure of the vir

279 binds carbonic anhydrase IX, a cell surface glycoprotein ubiquitously expressed in clear cell renal

280 This glycoprotein undergoes a major structural shift from the

281 f the host cell, a process mediated by viral glycoproteins upon binding to cognate host receptors or

282 ormed glycoproteomics on endogenous parasite glycoproteins using sequential endoglycosidase H and pep

283 stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine (rVSVG-ZEBOV-GP) across a 6 log10 d

284 n on the platelet-specific collagen receptor glycoprotein VI (GPVI) as a potential antithrombotic tar

285 FLA4 functions as a soluble glycoprotein via its carboxy-proximal Fas1 domain and it

286 Blood loss is prevented by the multidomain glycoprotein von Willebrand factor (VWF), which binds ex

287 peatedly replacing its dense variant surface glycoprotein (VSG) coat from its large genomic VSG reper

288 dense coat that comprises a variant surface glycoprotein (VSG).

289 A detailed description of the complete glycoprotein was achieved by combining crystallographic

290 creased PB platelet-derived growth factor BB glycoprotein was associated with increased BM function,

291 isition method when the amount of the target glycoprotein was limited in a sample of high complexity.

292 tric mean titers of antibodies against ZEBOV glycoprotein were higher in the groups that received 20

293 f VSVDeltaG viruses expressing Nipah G and F glycoproteins were lethal within the brain within a surp

294 llular prion protein (PrP(C)) is a mammalian glycoprotein which is usually found anchored to the plas

295 nfluenza virus target the hemagglutinin (HA) glycoprotein, which is the major antigen on the surface

296 aused by the fusogenic activity of the viral glycoprotein, which results in fusion of neurons and gli

297 The neuraminidase (NA) surface glycoprotein, while diverse, has a conserved enzymatic s

298 preparations of human cells corresponds to a glycoprotein with a molecular mass of 150 kDa.

299 s study is that a region in the rabies virus glycoprotein, with homologies to snake toxins, has the a

300 At the 2x10(11) particle-unit dose, glycoprotein Zaire-specific antibody responses were in t